Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

JERUSALEM, March 17, 2025 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology (I&I) biological products and in providing CDMO services through its Scinai Bioservices unit, today announced that it will be meeting with investors, showcasing its innovative I&I product pipeline in partnership meetings and exhibiting its CDMO boutique services at the BIO-Europe Spring 2025 conference, taking place March 17-19 in Milan, Italy.

Scinai's CEO, Mr. Amir Reichman, CTO, Dr. Dalit Weinstein-Fischer and Business Development Director, Mr. Solomon Gahtan will be holding meetings during the conference days with:

• Potential pharma partners in the field of I&I and dermatology interested in co-developing or in-licensing one of Scinai's innovative NanoAbs.
• Prospective clients of the company's end-to-end biologics CDMO services.
• Institutional and private investors interested in Scinai's value proposition.

Additional interested parties are encouraged to schedule a meeting through the conference partnering platform or to email Scinai at bd@scinai.com to schedule a meeting. Throughout the conference, Scinai will also be available at exhibitor booth #22 to showcase its CDMO services.

About Scinai Bioservices CDMO
In 2024, Scinai launched its CDMO business unit, branded as Scinai Bioservices, operating from the Company's site in Jerusalem, Israel. This facility includes 1,850 square meters (approximately 20,000 square feet) of clean rooms and laboratories, all operating under cGMP conditions in compliance with European Medicines Agency (EMA) and FDA requirements.

Since its inception, the CDMO unit has executed drug development projects for multiple biotech companies. These activities have included upstream and downstream process development, scale-up, analytical methods development and drug manufacturing for pre-clinical and clinical trials. Additionally, the Company has partnered with Ayana Pharma to provide liposomal encapsulated drug development services.

Scinai's U.S. subsidiary, Scinai Bioservices Inc., aims to serve U.S. based early-stage biotech companies by providing the required CDMO services that are currently in short supply. Scinai Bioservices Inc. allows early-stage biotech startups, supported by U.S. government grant funding, to use their grant money, avoiding any concerns related to the BIOSECURE Act.

About Scinai Immunotherapeutics
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique Biologics CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. Company website: www.scinai.com.

Company Contacts
Investor Relations | +972 8 930 2529 | ir@scinai.com
CDMO and Partnering | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to; the risk that we won't raise any capital under SEPA or that we will not otherwise benefit from the SEPA as currently anticipated; lower than anticipated revenues of Scinai's CDMO business; the risk that Scinai's expanded presence in the U.S. will not significantly enhance the prospects of its CDMO unit; the risk that the Company will otherwise be unable to remain compliant with the continued listing requirements of Nasdaq; failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study for psoriasis, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Photo - https://mma.prnewswire.com/media/2642473/Scinai_Immunotherapeutics_Ltd.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/scinai-to-connect-with-investors-showcase-its-innovative-ii-pipeline-and-its-boutique-cgmp-biologics-cdmo-during-bio-europe-spring-2025-302402918.html

SOURCE Scinai Immunotherapeutics Ltd.